–
Apimeds Pharmaceuticals US, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.02
FY22:
−0.64
FY23:
−0.75
FY24:
−1.28
FY25:
−11.9
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.02
FY22:
−0.64
FY23:
−0.74
FY24:
−1.27
FY25:
−11.8
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.03
FY22:
−0.67
FY23:
−0.78
FY24:
−1.39
FY25:
−6.00
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.03
FY22:
−0.67
FY23:
−0.78
FY24:
−1.39
FY25:
−6.00
All amounts in millions USD FY21, FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.